NPI: 1073599478 · SEATTLE, WA 98122 · Clinical Medical Laboratory · NPI assigned 12/16/2005
Authorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
| Authorized Official | WILLIAMS, KIMBERLY (VP) |
| NPI Enumeration Date | 12/16/2005 |
Other providers sharing the same authorized official: WILLIAMS, KIMBERLY
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 2,063,155 | $22.84M |
| 2019 | 2,303,868 | $24.44M |
| 2020 | 2,102,135 | $24.12M |
| 2021 | 2,598,973 | $32.39M |
| 2022 | 2,667,794 | $29.34M |
| 2023 | 2,761,412 | $27.37M |
| 2024 | 2,563,932 | $26.19M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 188,977 | 168,426 | $13.40M |
| 80050 | General health panel | 434,731 | 418,859 | $11.44M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 353,274 | 330,059 | $9.39M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 352,996 | 329,885 | $9.28M |
| 80061 | Lipid panel | 923,511 | 887,084 | $7.91M |
| 80053 | Comprehensive metabolic panel | 996,117 | 934,391 | $6.83M |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | 18,024 | 17,807 | $6.72M |
| 84443 | Thyroid stimulating hormone (TSH) | 564,936 | 541,717 | $6.25M |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 356,441 | 340,152 | $5.90M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 864,527 | 799,109 | $4.45M |
| 83036 | Hemoglobin; glycosylated (A1C) | 753,037 | 724,303 | $4.40M |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 137,653 | 133,253 | $3.50M |
| 36415 | Collection of venous blood by venipuncture | 1,581,701 | 1,426,759 | $3.37M |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 281,212 | 268,230 | $3.37M |
| 86803 | 340,545 | 324,942 | $3.22M | |
| 86480 | 76,931 | 71,299 | $2.99M | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 135,808 | 131,640 | $2.86M |
| 87086 | Culture, bacterial; quantitative colony count, urine | 426,545 | 398,641 | $2.49M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 41,464 | 38,408 | $2.33M |
| 82728 | 234,780 | 225,094 | $2.13M | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 47,521 | 42,431 | $2.06M |
| 80081 | 36,550 | 34,285 | $2.02M | |
| 84439 | 312,581 | 298,646 | $1.92M | |
| 84403 | 107,291 | 101,412 | $1.89M | |
| 83013 | 35,998 | 35,228 | $1.73M | |
| 82607 | 167,930 | 161,833 | $1.70M | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 23,821 | 21,882 | $1.45M |
| 87507 | 4,524 | 4,372 | $1.24M | |
| 82670 | 58,626 | 55,740 | $1.16M | |
| 87340 | 174,398 | 164,348 | $1.15M | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 3,801 | 3,732 | $1.13M |
| 83550 | 182,799 | 175,999 | $1.07M | |
| 82746 | 107,695 | 103,672 | $1.06M | |
| 88142 | 61,146 | 58,956 | $1.04M | |
| 80074 | 34,353 | 32,390 | $1.02M | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 100,921 | 91,717 | $982K |
| 80048 | Basic metabolic panel (calcium, ionized) | 180,685 | 167,389 | $973K |
| 85027 | 211,581 | 201,471 | $902K | |
| 87902 | 5,159 | 4,913 | $891K | |
| 86780 | 102,094 | 99,283 | $891K | |
| 82274 | 79,418 | 76,938 | $888K | |
| 83970 | 32,730 | 31,284 | $887K | |
| 87186 | 135,514 | 128,168 | $882K | |
| 84702 | 81,101 | 60,317 | $854K | |
| 83540 | 195,551 | 187,425 | $839K | |
| 80055 | 21,448 | 20,862 | $835K | |
| 84153 | 74,276 | 70,576 | $832K | |
| 87081 | 160,442 | 156,055 | $825K | |
| 87522 | Neg quan hep c or qual rna | 29,033 | 27,833 | $818K |
| 83880 | 35,171 | 32,925 | $794K | |
| 86235 | 12,328 | 11,733 | $789K | |
| 84402 | 45,269 | 42,948 | $787K | |
| 86003 | 11,015 | 10,651 | $779K | |
| 82570 | 222,622 | 213,071 | $776K | |
| 87088 | 131,122 | 124,357 | $735K | |
| 83001 | 55,131 | 53,082 | $732K | |
| 84146 | 51,728 | 49,122 | $728K | |
| 87480 | 50,045 | 48,239 | $725K | |
| 84481 | 62,315 | 59,144 | $717K | |
| 87660 | 50,037 | 48,232 | $712K | |
| 86704 | 89,548 | 83,796 | $698K | |
| 87510 | 50,040 | 48,235 | $697K | |
| 82043 | 180,555 | 175,006 | $695K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 30,255 | 29,472 | $687K |
| 86706 | 95,389 | 89,287 | $667K | |
| 87536 | 10,913 | 10,728 | $663K | |
| 87077 | 108,104 | 102,963 | $621K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 2,271 | 2,193 | $566K |
| 86762 | 63,105 | 60,312 | $562K | |
| 88342 | 8,650 | 8,191 | $527K | |
| 86140 | 143,780 | 134,341 | $525K | |
| 87070 | 79,538 | 76,065 | $518K | |
| 83002 | 37,173 | 35,708 | $490K | |
| 88141 | 32,836 | 32,011 | $489K | |
| 86592 | 166,491 | 155,773 | $483K | |
| 86708 | 58,986 | 55,126 | $475K | |
| 86038 | 55,947 | 54,611 | $475K | |
| 86787 | 43,388 | 41,084 | $419K | |
| 84144 | 27,483 | 24,864 | $403K | |
| 86376 | 38,556 | 36,857 | $400K | |
| 86696 | 26,306 | 25,183 | $375K | |
| 81001 | 166,741 | 157,120 | $358K | |
| 82784 | 34,218 | 32,315 | $344K | |
| 83516 | 20,122 | 19,293 | $342K | |
| 86850 | 60,783 | 58,033 | $334K | |
| 82950 | 90,538 | 87,366 | $330K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 15,296 | 9,348 | $325K |
| 84480 | 31,952 | 30,455 | $318K | |
| 80076 | 53,364 | 50,651 | $305K | |
| 82627 | 19,039 | 18,190 | $300K | |
| 83735 | 64,012 | 55,801 | $284K | |
| 83655 | 30,199 | 29,747 | $263K | |
| 83690 | 52,978 | 50,980 | $261K | |
| 86769 | 8,465 | 7,613 | $257K | |
| 85652 | 136,154 | 127,988 | $255K | |
| 86665 | 10,480 | 9,958 | $255K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 5,747 | 5,636 | $250K |
| 86800 | 21,329 | 20,549 | $241K | |
| 86200 | 25,811 | 25,303 | $236K | |
| 82951 | 23,859 | 22,864 | $233K | |
| 86695 | 23,899 | 22,914 | $226K | |
| 88312 | 4,048 | 3,827 | $220K | |
| 86360 | 6,622 | 6,298 | $220K | |
| 82533 | 17,671 | 16,488 | $208K | |
| 86160 | 13,596 | 12,795 | $205K | |
| 86317 | 20,632 | 19,700 | $204K | |
| 86431 | 48,685 | 47,048 | $201K | |
| 84550 | 67,598 | 63,026 | $200K | |
| 82105 | 17,514 | 16,394 | $199K | |
| 87075 | 28,581 | 27,438 | $197K | |
| 88341 | 2,508 | 2,367 | $192K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 3,029 | 2,869 | $185K |
| 85610 | 67,585 | 57,790 | $182K | |
| 87517 | 5,920 | 5,842 | $177K | |
| 87150 | 23,146 | 22,357 | $166K | |
| 87209 | 12,517 | 12,175 | $166K | |
| 87427 | 19,673 | 18,919 | $165K | |
| 84450 | 51,146 | 47,181 | $164K | |
| 84436 | 35,498 | 33,594 | $163K | |
| 84460 | 47,906 | 44,263 | $163K | |
| 82565 | 51,507 | 47,392 | $162K | |
| 86141 | 17,447 | 16,362 | $154K | |
| 84445 | 4,058 | 4,008 | $153K | |
| 86147 | 3,525 | 3,308 | $153K | |
| 86765 | 17,423 | 16,647 | $153K | |
| 83721 | 34,253 | 33,252 | $148K | |
| 86364 | 11,305 | 11,034 | $145K | |
| 82024 | 5,108 | 4,831 | $140K | |
| 86709 | 18,190 | 17,458 | $139K | |
| 87046 | 20,130 | 18,979 | $137K | |
| 82247 | 47,981 | 39,837 | $137K | |
| 86735 | 15,265 | 14,589 | $134K | |
| 87045 | 19,629 | 18,885 | $132K | |
| 86361 | 7,308 | 7,007 | $130K | |
| 80164 | 16,602 | 14,547 | $130K | |
| 84156 | 49,135 | 44,977 | $126K | |
| 82248 | 40,360 | 34,903 | $125K | |
| 83525 | 14,893 | 14,148 | $122K | |
| 86870 | 3,658 | 3,437 | $120K | |
| 86677 | 6,910 | 6,615 | $120K | |
| 82977 | 27,736 | 25,189 | $118K | |
| 85060 | 10,161 | 9,877 | $117K | |
| 84100 | 39,017 | 30,070 | $115K | |
| 86258 | 6,569 | 6,363 | $115K | |
| 84270 | 7,273 | 6,973 | $110K | |
| 86225 | 12,378 | 12,059 | $109K | |
| 87255 | 4,130 | 3,995 | $108K | |
| 82150 | 22,673 | 21,750 | $107K | |
| 87625 | 4,694 | 4,600 | $106K | |
| 81329 | 1,627 | 1,607 | $104K | |
| 84681 | 7,077 | 6,787 | $103K | |
| 80069 | 19,549 | 17,915 | $102K | |
| 84165 | 14,224 | 13,546 | $100K | |
| 82239 | 7,703 | 6,498 | $99K | |
| 86900 | 53,548 | 50,955 | $99K | |
| 87493 | 4,003 | 3,837 | $98K | |
| 86901 | 53,613 | 51,015 | $98K | |
| 80178 | 22,778 | 20,107 | $96K | |
| 82550 | 21,065 | 19,366 | $95K | |
| 82947 | 36,784 | 34,089 | $94K | |
| 86664 | 8,272 | 7,921 | $93K | |
| 83498 | 4,653 | 4,603 | $92K | |
| 83090 | 8,227 | 7,768 | $89K | |
| 85730 | 23,689 | 22,202 | $88K | |
| 84703 | 16,587 | 15,392 | $88K | |
| 82378 | 6,518 | 5,759 | $86K | |
| 84154 | 7,624 | 7,303 | $85K | |
| 87210 | 23,313 | 22,471 | $85K | |
| 84520 | 34,322 | 31,197 | $85K | |
| 87177 | 12,600 | 12,245 | $82K | |
| 82652 | 5,357 | 4,982 | $81K | |
| 82785 | 6,753 | 6,605 | $78K | |
| 83615 | 21,333 | 18,821 | $78K | |
| 82040 | 27,852 | 25,641 | $78K | |
| 84425 | 5,402 | 5,319 | $77K | |
| 84075 | 26,663 | 24,455 | $76K | |
| 84479 | 17,418 | 16,481 | $75K | |
| 86304 | 5,309 | 4,984 | $74K | |
| 82672 | 5,021 | 4,820 | $74K | |
| 86705 | 8,988 | 8,594 | $72K | |
| 86334 | 5,094 | 4,844 | $72K | |
| 81596 | 1,932 | 1,918 | $71K | |
| 87205 | 22,195 | 21,323 | $71K | |
| 82310 | 24,766 | 22,716 | $69K | |
| 84155 | 30,147 | 27,816 | $66K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 898 | 866 | $66K |
| 88304 | 2,864 | 2,670 | $65K | |
| 83921 | 5,293 | 5,192 | $65K | |
| 88307 | 400 | 380 | $64K | |
| 83520 | 5,995 | 5,788 | $64K | |
| 84466 | 7,372 | 7,111 | $63K | |
| 88185 | 213 | 206 | $63K | |
| 86300 | 3,651 | 3,151 | $62K | |
| 80197 | 7,209 | 5,358 | $61K | |
| 82330 | 6,558 | 6,279 | $59K | |
| 86341 | 2,809 | 2,653 | $58K | |
| 82679 | 3,371 | 3,289 | $58K | |
| 82140 | 6,016 | 5,387 | $58K | |
| 84482 | 5,024 | 4,877 | $57K | |
| 86146 | 1,311 | 1,225 | $57K | |
| 87324 | 6,523 | 6,276 | $55K | |
| 83993 | 3,905 | 3,840 | $55K | |
| 82952 | 18,083 | 17,336 | $54K | |
| 87338 | 5,486 | 5,402 | $53K | |
| 85379 | 7,233 | 7,003 | $51K | |
| 84305 | 3,245 | 3,198 | $51K | |
| 82390 | 6,624 | 6,328 | $49K | |
| 84295 | 19,156 | 17,388 | $49K | |
| 86663 | 5,006 | 4,730 | $49K | |
| 82103 | 4,956 | 4,732 | $47K | |
| 82435 | 18,771 | 17,034 | $47K | |
| 87535 | 2,114 | 2,076 | $46K | |
| 82088 | 1,565 | 1,541 | $46K | |
| 87521 | Neg quan hep c or qual rna | 1,740 | 1,712 | $45K |
| 85045 | 16,612 | 15,673 | $45K | |
| 83521 | 1,736 | 1,557 | $44K | |
| 84134 | 4,229 | 3,124 | $43K | |
| 87529 | 1,662 | 1,612 | $43K | |
| 80051 | 9,131 | 8,409 | $43K | |
| 87350 | 5,226 | 5,032 | $42K | |
| 84630 | 5,432 | 5,305 | $42K | |
| 87329 | 4,706 | 4,630 | $42K | |
| 82626 | 2,300 | 2,256 | $42K | |
| 87486 | 1,666 | 1,607 | $41K | |
| 87581 | 1,657 | 1,599 | $41K | |
| 88230 | 490 | 477 | $40K | |
| 36416 | 22,774 | 20,884 | $40K | |
| 86357 | 1,665 | 1,561 | $39K | |
| 86645 | 3,164 | 3,054 | $39K | |
| 86644 | 3,781 | 3,593 | $39K | |
| 86702 | 4,485 | 4,242 | $38K | |
| 87184 | 7,139 | 6,965 | $38K | |
| 84132 | 14,206 | 12,681 | $38K | |
| 83021 | 2,792 | 2,734 | $38K | |
| 82172 | 3,088 | 3,000 | $37K | |
| 84207 | 2,026 | 1,995 | $37K | |
| 88313 | 876 | 848 | $36K | |
| 82525 | 4,322 | 4,198 | $36K | |
| 81025 | 7,335 | 6,975 | $36K | |
| G0306 | Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count | 6,847 | 6,493 | $35K |
| 88112 | 1,149 | 1,019 | $34K | |
| 88262 | 442 | 429 | $34K | |
| 82397 | 3,363 | 3,316 | $34K | |
| 86301 | 2,484 | 2,181 | $34K | |
| 86593 | 10,967 | 10,580 | $33K | |
| 85014 | 18,256 | 17,425 | $31K | |
| 81003 | 21,460 | 20,535 | $31K | |
| 85018 | 17,379 | 16,661 | $29K | |
| 86682 | 2,961 | 2,942 | $29K | |
| 86707 | 3,465 | 3,362 | $29K | |
| 84478 | 8,120 | 6,066 | $29K | |
| 85246 | 1,630 | 1,618 | $28K | |
| 85245 | 1,588 | 1,576 | $27K | |
| 84166 | 2,267 | 2,189 | $27K | |
| 86256 | 2,341 | 2,260 | $27K | |
| 86381 | 1,434 | 1,421 | $27K | |
| 86618 | 1,567 | 1,536 | $27K | |
| 86359 | 1,003 | 955 | $25K | |
| 87641 | 949 | 935 | $25K | |
| 84432 | 2,168 | 2,127 | $25K | |
| 87563 | 1,370 | 1,352 | $25K | |
| 80177 | 2,839 | 2,716 | $25K | |
| 86308 | 6,380 | 6,159 | $25K | |
| 87040 | 2,711 | 2,477 | $24K | |
| 80175 | 2,758 | 2,666 | $24K | |
| 84484 | 3,114 | 2,925 | $24K | |
| 80156 | 2,822 | 2,640 | $24K | |
| 85240 | 1,762 | 1,738 | $24K | |
| 81374 | 4,818 | 4,747 | $23K | |
| 86777 | 2,225 | 2,081 | $23K | |
| 84244 | 1,451 | 1,430 | $23K | |
| 83020 | 2,409 | 2,382 | $23K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1,090 | 1,038 | $23K |
| 86701 | 4,089 | 3,852 | $23K | |
| 83010 | 2,499 | 2,385 | $22K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 3,595 | 3,499 | $22K |
| 87101 | 3,808 | 3,655 | $22K | |
| G0307 | Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) | 5,001 | 4,755 | $22K |
| 82787 | 1,191 | 1,106 | $22K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 471 | 441 | $21K |
| 83883 | 2,331 | 2,225 | $21K | |
| 83014 | 3,800 | 3,717 | $21K | |
| 82374 | 8,044 | 7,624 | $21K | |
| 82166 | 548 | 542 | $20K | |
| 80185 | 2,499 | 2,119 | $20K | |
| 82677 | 1,134 | 1,118 | $20K | |
| 80159 | 1,915 | 1,685 | $20K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | 5,758 | 5,507 | $19K |
| 82653 | 994 | 979 | $19K | |
| 86694 | 1,794 | 1,769 | $18K | |
| 86356 | 1,200 | 1,113 | $18K | |
| 84590 | 2,319 | 2,280 | $18K | |
| 82465 | 7,259 | 6,416 | $18K | |
| 87076 | 3,071 | 2,976 | $17K | |
| 85007 | 7,308 | 6,981 | $17K | |
| 84080 | 1,704 | 1,655 | $17K | |
| 82553 | 2,107 | 1,989 | $17K | |
| 86778 | 1,548 | 1,445 | $17K | |
| 87538 | 655 | 638 | $16K | |
| 86015 | 1,733 | 1,711 | $16K | |
| 86037 | 699 | 674 | $16K | |
| 81241 | 531 | 525 | $15K | |
| 80299 | 868 | 819 | $14K | |
| 86162 | 1,007 | 994 | $14K | |
| 85660 | 3,389 | 3,276 | $14K | |
| 87206 | 3,474 | 3,133 | $14K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1,467 | 1,434 | $13K |
| 86336 | 1,084 | 1,075 | $12K | |
| 83718 | 2,303 | 2,233 | $12K | |
| 86060 | 2,292 | 2,151 | $12K | |
| 81015 | 5,829 | 5,614 | $12K | |
| 82157 | 546 | 533 | $12K | |
| 86255 | 1,339 | 1,308 | $12K | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 4,682 | 4,554 | $12K |
| 85049 | 4,741 | 4,184 | $11K | |
| 84446 | 1,146 | 1,129 | $11K | |
| 83789 | 713 | 703 | $11K | |
| 86008 | 466 | 459 | $11K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 116 | 112 | $11K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 420 | 401 | $11K |
| 82985 | 1,165 | 1,080 | $11K | |
| 0352U | 73 | 72 | $9K | |
| 86337 | 586 | 577 | $9K | |
| 82340 | 2,098 | 2,009 | $9K | |
| 81256 | 291 | 285 | $9K | |
| 82705 | 2,353 | 2,245 | $9K | |
| 85613 | 1,129 | 1,089 | $8K | |
| 83935 | 1,810 | 1,716 | $8K | |
| 87254 | 561 | 538 | $8K | |
| 86738 | 444 | 428 | $8K | |
| 83695 | 1,133 | 1,122 | $8K | |
| 82085 | 1,152 | 1,125 | $8K | |
| 82668 | 632 | 627 | $8K | |
| 86231 | 714 | 707 | $8K | |
| 86036 | 779 | 768 | $8K | |
| 85384 | 1,224 | 1,126 | $7K | |
| 0097U | 157 | 154 | $7K | |
| 88189 | 182 | 175 | $7K | |
| 82164 | 682 | 668 | $7K | |
| 80162 | 894 | 828 | $7K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 70 | 70 | $7K |
| 89055 | 2,034 | 1,995 | $7K | |
| 82731 | 120 | 113 | $6K | |
| 88184 | 213 | 206 | $6K | |
| 83631 | 464 | 458 | $6K | |
| 84410 | 182 | 174 | $6K | |
| 82955 | 820 | 807 | $6K | |
| 87328 | 689 | 668 | $6K | |
| 86880 | 1,649 | 1,569 | $6K | |
| 87799 | 369 | 326 | $6K | |
| 84300 | 1,641 | 1,557 | $5K | |
| 83930 | 1,213 | 1,141 | $5K | |
| 84145 | 319 | 304 | $5K | |
| 87900 | 52 | 52 | $5K | |
| 99199 | Unlisted special service, procedure or report | 3,103 | 2,887 | $5K |
| 82104 | 472 | 455 | $5K | |
| 86658 | 199 | 169 | $4K | |
| 80305 | 583 | 538 | $4K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 3,400 | 3,244 | $4K |
| 80183 | 454 | 447 | $4K | |
| 86617 | 177 | 169 | $4K | |
| 81401 | 71 | 69 | $4K | |
| 80202 | 434 | 216 | $4K | |
| 85048 | 2,151 | 2,034 | $4K | |
| 80165 | 1,318 | 1,259 | $4K | |
| 86671 | 376 | 368 | $4K | |
| 0099U | 90 | 89 | $4K | |
| 87481 | 199 | 132 | $3K | |
| 82747 | 300 | 297 | $3K | |
| 85004 | 754 | 705 | $3K | |
| 82552 | 359 | 342 | $3K | |
| 87106 | 429 | 413 | $3K | |
| 87230 | 217 | 213 | $3K | |
| 86355 | 129 | 122 | $3K | |
| 82610 | 256 | 251 | $3K | |
| 87420 | 342 | 341 | $3K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | 3,174 | 3,027 | $3K |
| 84255 | 163 | 160 | $3K | |
| 89060 | 552 | 531 | $3K | |
| 87207 | 629 | 606 | $3K | |
| 89051 | 669 | 644 | $3K | |
| 83835 | 215 | 214 | $3K | |
| 87807 | 272 | 262 | $3K | |
| 82681 | 126 | 124 | $2K | |
| 85598 | 679 | 664 | $2K | |
| 85041 | 985 | 961 | $2K | |
| 82575 | 262 | 251 | $2K | |
| 85670 | 510 | 504 | $2K | |
| 82656 | 222 | 216 | $2K | |
| 80184 | 188 | 137 | $2K | |
| 84140 | 140 | 135 | $2K | |
| 84163 | 157 | 154 | $2K | |
| 86804 | 160 | 159 | $2K | |
| 81291 | 225 | 219 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 23 | 19 | $1K |
| 83704 | 80 | 77 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 43 | 43 | $1K |
| 87252 | 59 | 58 | $1K | |
| 87497 | 41 | 37 | $1K | |
| 83986 | 469 | 456 | $1K | |
| G0124 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | 231 | 221 | $1K |
| 83825 | 90 | 90 | $1K | |
| 82542 | 70 | 67 | $1K | |
| 84378 | 107 | 105 | $976.25 | |
| 87116 | 127 | 90 | $908.16 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | 892 | 860 | $885.19 |
| 81243 | 52 | 52 | $842.73 | |
| 86747 | 37 | 36 | $822.98 | |
| 83088 | 42 | 41 | $781.82 | |
| 81240 | 26 | 24 | $610.08 | |
| 86335 | 30 | 30 | $557.46 | |
| 84597 | 56 | 54 | $507.14 | |
| 85306 | 40 | 39 | $472.25 | |
| 80158 | 30 | 24 | $428.85 | |
| 80203 | 44 | 41 | $426.32 | |
| 81479 | Unlisted molecular pathology procedure | 25 | 25 | $416.74 |
| 83625 | 55 | 52 | $410.21 | |
| 82642 | 58 | 56 | $403.83 | |
| 84133 | 127 | 122 | $369.94 | |
| 87015 | 71 | 55 | $326.57 | |
| S3600 | Stat laboratory request (situations other than s3601) | 5,751 | 4,553 | $252.90 |
| 85385 | 27 | 27 | $227.14 | |
| 82436 | 64 | 63 | $225.84 | |
| 85303 | 26 | 26 | $212.09 | |
| 87172 | 60 | 54 | $201.90 | |
| 81002 | 91 | 87 | $191.94 | |
| 84181 | 13 | 13 | $180.78 | |
| 82175 | 14 | 14 | $179.84 | |
| 82232 | 12 | 12 | $168.69 | |
| 83003 | 14 | 14 | $156.79 | |
| 87109 | 12 | 12 | $144.35 | |
| 83519 | 15 | 12 | $136.17 | |
| 86340 | 13 | 13 | $135.68 | |
| 86790 | 13 | 12 | $124.30 | |
| 80186 | 14 | 13 | $115.82 | |
| 80235 | 13 | 13 | $110.24 | |
| 87899 | 14 | 12 | $107.79 | |
| 86606 | 12 | 12 | $107.61 | |
| 82180 | 13 | 13 | $78.96 | |
| 85300 | 13 | 12 | $77.38 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 606 | 480 | $59.11 |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 510 | 390 | $50.90 |
| 83874 | 12 | 12 | $43.86 | |
| 87220 | 15 | 13 | $32.89 | |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 16 | 16 | $0.00 |
| 81377 | 42 | 42 | $0.00 | |
| 80356 | 150 | 134 | $0.00 | |
| 80365 | 152 | 136 | $0.00 | |
| 80361 | 156 | 140 | $0.00 |